# Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

> **NCT06186648** · PHASE2 · RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 40 (estimated)

## Conditions studied

- Richter Syndrome

## Interventions

- **DRUG:** Glofitamab + Obinutuzumab

## Key facts

- **NCT ID:** NCT06186648
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-21
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186648, "Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06186648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*